Preclinical studies have demonstrated that LLL12B effectively inhibits tumor cell growth, migration, and invasion across various cancer types including TNBC [22], medulloblastoma [20], ovarian cancer [23], etc., highlighting its potential as a novel therapeutic agent for STAT3-driven malignancies. This evidence concerns the gene STAT3 and ovarian cancer.